Does Multaq (dronedarone) affect serum creatinine levels?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Does Multaq Affect Creatinine?

Yes, Multaq (dronedarone) consistently increases serum creatinine levels, but this elevation is typically benign and does not reflect true kidney damage—it results from inhibition of creatinine's tubular secretion in the kidney.

Mechanism of Creatinine Elevation

Dronedarone blocks the organic cation transporter (OCT2) and multidrug and toxin extrusion proteins (MATE1/2-K) in the renal tubules, which normally secrete creatinine 1. This pharmacologic effect causes:

  • Small increases of approximately 0.1 mg/dL in creatinine levels
  • Rapid onset with plateau reached after 7 days
  • Reversible upon drug discontinuation 1

Clinical Trial Data

In placebo-controlled trials involving 6,285 patients, 51% of dronedarone-treated patients experienced early creatinine increases ≥10% compared to only 21% in the placebo group 1. This represents a consistent and expected finding across all dronedarone studies 2.

Distinguishing Benign from Pathologic Increases

Benign Tubular Secretion Inhibition:

  • Stable cystatin C levels (cystatin C is not affected by tubular secretion inhibitors) 3
  • Modest elevation (~0.1 mg/dL increase)
  • Occurs within first 7 days
  • No other signs of renal dysfunction

True Renal Impairment (Requires Action):

  • Marked increases in serum creatinine beyond the expected 0.1 mg/dL
  • Pre-renal azotemia or acute renal failure
  • Often occurs in the setting of heart failure or hypovolemia 1
  • Cases reported within 6-13 days of initiation 4
  • Rising cystatin C levels would indicate true GFR decline 3

Monitoring Recommendations

According to the 2023 ACC/AHA/ACCP/HRS guidelines, no routine creatinine monitoring is specifically mandated for dronedarone beyond standard clinical practice 5, 6. However, the FDA label clearly states to monitor renal function periodically 1.

Practical Monitoring Approach:

  • Baseline creatinine before initiation
  • Recheck at 7-14 days (when plateau occurs)
  • If increase is modest (~0.1 mg/dL) and patient is stable, this is expected
  • Consider cystatin C measurement if concerned about true renal dysfunction 3
  • Monitor more frequently in patients with:
    • Pre-existing renal impairment
    • Heart failure
    • Hypovolemia
    • Concurrent nephrotoxic medications

Critical Warnings

Discontinue dronedarone if:

  • Marked creatinine increases beyond expected 0.1 mg/dL elevation
  • Signs of acute renal failure develop
  • Heart failure worsens (dronedarone increases mortality in severe heart failure) 7
  • Pre-renal azotemia occurs 1

Common Pitfall to Avoid

Do not automatically discontinue dronedarone or adjust dosing for the expected small creatinine rise. The modest elevation (~0.1 mg/dL) does not represent true kidney injury and does not require intervention 1, 3. However, remain vigilant for larger increases that signal true renal impairment, particularly in the first two weeks of therapy and in high-risk patients (heart failure, volume depletion) 4, 7.

The key is distinguishing the pharmacologic effect (benign, expected, small) from pathologic renal injury (requires discontinuation, associated with heart failure/hypovolemia, larger magnitude).

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.